Hanseatic Portfolio Expansion
Hanseatic Management Services Expands Multi-Million Stakes Across EchoStar, Amkor, Krystal Biotech, and SPDR ETF
Anonymous
Key Points
1
Heartland Advisors Inc. trimmed its Lincoln Educational Services position by 72.3% in the first quarter, selling 932,735 shares and ending with 357,265 shares valued at about $14.53 million.
2
EchoStar Corp. CEO Hamid Akhavan sold 52,586 shares on June 5, reducing his direct ownership to 865,633 shares (roughly $104.74 million at the time) and the sale was conducted under a pre-arranged Rule 10b5-1 plan; insiders collectively own about 55.90% of the stock.
3
Royal Bank of Canada raised its Amkor Technology stake by 100.6% in the first quarter, now holding 19,345 shares valued at about $349,000 after adding more shares; overall, institutional investors own about 42.76% of Amkor’s stock.
4
Hanseatic also expanded its SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) position by purchasing 37,901 shares for about $2.24 million, reinforcing its stance as the ETF’s 9th largest holding; the fund traded with an opening price of about $66.18 and notable technical levels (50-day MA $65.67, 200-day MA $62.83).
5
Krystal Biotech, Inc. received a new Hanseatic stake of 2,997 shares for roughly $774,000; KRYS stock context shows a one-year range of $130.50–$382.54, with a market cap around $10.46 billion and a P/E near 47.44; hedge funds and institutions own about 86.29% of the stock.
Hanseatic Management Services Inc. has quietly built new positions across four US equities, with total new investments topping $5 million in the first quarter, according to Watchlist News. The firm's biggest new bet was a $2.24 million stake in the SPDR Portfolio S&P 400 Mid Cap ETF, making it the ETF's ninth largest holder.
The purchases span satellites, semiconductors, biotech, and a broad mid-cap index fund. Together, they signal a deliberate push by Hanseatic into growth-oriented corners of the US market.
Hanseatic Drops $5 Million Across Four New Positions
Hanseatic bought 8,952 shares of EchoStar Corporation for roughly $1.05 million in Q1, according to Watchlist News. EchoStar trades on the Nasdaq under the ticker SATS. The firm also added 20,432 shares of chip maker Amkor Technology, worth about $920,000.
The firm's newest biotech bet was 2,997 shares of Krystal Biotech, valued at about $774,000. Krystal carries a market cap near $10.46 billion and a price-to-earnings ratio of 47.44. Its stock has swung widely over the past year, trading between $130.50 and $382.54.
Mid-Cap ETF Bet Becomes Hanseatic's Largest Single Move
The SPDR Portfolio S&P 400 Mid Cap ETF, ticker SPMD, received Hanseatic's biggest allocation. The firm bought 37,901 shares for about $2.24 million, landing it at the ninth spot among the ETF's largest holders, per Watchlist News.
The ETF opened at about $66.18. Its 50-day moving average sits at $65.67 and its 200-day average at $62.83. Those levels suggest the fund is trading above both short- and long-term trend lines, a sign of recent strength.
EchoStar CEO Sells Shares as Insider Ownership Stays High
While Hanseatic was buying into EchoStar, the company's CEO was selling. Hamid Akhavan sold 52,586 shares on June 5 under a pre-arranged Rule 10b5-1 plan. That is a legal plan set up in advance to avoid insider trading concerns. After the sale, he still held 865,633 shares worth about $104.74 million.
Despite the CEO's sale, insiders as a group still own about 55.90% of EchoStar's stock. That is a very high insider ownership rate. It suggests those closest to the company still have strong confidence in its direction.
Other Big Investors Shift Positions in the Same Names
Hanseatic was not alone in moving on these stocks. Royal Bank of Canada more than doubled its Amkor Technology stake in Q1, raising it by 100.6% to 19,345 shares worth about $349,000. Overall, institutions own about 42.76% of Amkor's stock, per Watchlist News.
On the other side, Heartland Advisors cut its Lincoln Educational Services position by 72.3%. It sold 932,735 shares, leaving it with 357,265 shares valued at about $14.53 million. Hedge funds and institutions own about 86.29% of Krystal Biotech, showing heavy professional interest in that name as well.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
7
Reach
22
A
AnonymousAuthor